Company news

Exelixis, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

January 8, 2025

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

January 5, 2025

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

November 26, 2024

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

November 25, 2024

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

November 6, 2024

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

October 28, 2024

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

October 14, 2024

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

October 14, 2024

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

October 13, 2024

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

September 15, 2024

Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024

September 14, 2024

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September

August 27, 2024

Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors

August 5, 2024

Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update

August 5, 2024

Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

July 22, 2024

Exelixis to Present at the William Blair 44th Annual Growth Stock Conference

May 27, 2024

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

May 19, 2024

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

April 29, 2024

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

April 15, 2024

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

February 26, 2024

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

February 5, 2024

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

January 31, 2024

Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

January 24, 2024

Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024

January 22, 2024

European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets

January 17, 2024

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

January 6, 2024

Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024

January 1, 2024

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023

December 6, 2023

Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

December 3, 2023

Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma

December 3, 2023

Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023

November 20, 2023

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

November 9, 2023

Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update

October 31, 2023

Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

October 21, 2023

Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023

October 17, 2023

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

September 11, 2023

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

August 23, 2023

Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

August 22, 2023

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

August 20, 2023

Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update

July 31, 2023

Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.

July 22, 2023

Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

July 17, 2023

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June

May 29, 2023

Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 8, 2023

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

May 6, 2023

Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023

May 2, 2023

Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders

April 30, 2023

Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

April 24, 2023

Exelixis Advances Board Refreshment Plan

April 12, 2023

Exelixis Reiterates Commitment to Shareholder Value Creation

April 4, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 11 decks. Every deck is listed under its year.